INTRODUCING IPS: A PROGNOSTIC BIOMARKER FOR PATIENTS ON ICI THERAPY /// LEARN MORE INTRODUCING IPS: A PROGNOSTIC BIOMARKER FOR PATIENTS ON ICI THERAPY /// LEARN MORE
ORDER A TEST Log In Contact Us

Tempus IO™

A comprehensive immunotherapy platform that provides actionable and cutting-edge services for life sciences partners advancing IO therapies, including antibody-drug conjugates (ADCs), TCR therapies, and immune checkpoint inhibitors (ICIs).

An all-in-one biomarker platform

Comprehensive real-world data (RWD)

~99% of whole transcriptome profiles contain at least one IO biomarker

Robust suite of IO biomarkers

10+ IO biomarkers available through Tempus sequencing

Advanced analytical tech

Leverage AI- and ML-based analytical tools to unlock actionable insights

Immune Profile Score (IPS)

First-of-its-kind  biomarker utilizing DNA and RNA to prognosticate ICI response

THURSDAY, DECEMBER 5  @  10 AM PT / 12 PM CT / 1 PM ET

Advancing IO therapeutics: The convergence of novel biomarkers and combination strategies

During this engaging session, you will: Examine the role novel biomarkers and combination treatment strategies play in understanding and enhancing the immune system's response to cancer; discover the significant developments that are helping to shape clinical trials and enhance patient outcomes in IO; and hear perspectives from industry experts on the potential of emerging therapies.

Register now

Insights delivered with every sample

Assess key aspects of the tumor microenvironment (TME) and understand resistance mechanisms using standard and novel biomarker data. Tempus IO data is included with applicable next-generation sequencing (NGS) assay orders to ensure comprehensive insights without the need for additional sample collection.

Download the Tempus IO overview to learn more

  • Tempus xT: Solid Tumor DNA Seq

    Tumor Mutational Burden (TMB)

    Microsatellite Instability (MSI)

    Neoantigen Prediction

    Human Leukocyte Antigen (HLA) Typing

    HLA Loss of Heterozygosity (LOH)

    Oncogenic Virus

    Mismatch Repair (MMR) Proteins by IHC1

    PD-L1 Protein quantification by IHC1

    Mechanisms of Tumor Resistance to Immunotherapy2

    Immune Profile Score (IPS): ICI response prognosticator (available with concurrent xT and xR orders)

  • Tempus xE: Whole Exome

    Tumor Mutational Burden (TMB)

    Microsatellite Instability (MSI)

    Neoantigen Prediction

    Human Leukocyte Antigen (HLA) Typing

    Oncogenic Virus

    Mismatch Repair (MMR) Proteins by IHC1

    PD-L1 Protein quantification by IHC1

    Mechanisms of Tumor Resistance to Immunotherapy2

  • Tempus xR: Whole Transcriptome RNA Seq

    Gene Expression Target Profiling3

    Neoantigen Prediction

    Immune Infiltration

    Oncogenic Virus

    T-cell Receptor / B-cell Receptor Repertoire

    Mismatch Repair (MMR) Proteins by IHC1

    PD-L1 Protein quantification by IHC1

    Immune Profile Score (IPS): ICI response prognosticator (available with concurrent xT and xR orders)

  • Tempus xF/xF+: Liquid Biopsies

    Blood Tumor Mutational Burden (bTMB) (xF+ only)

    Microsatellite Instability (MSI) high status (xF/xF+)

Tumor Mutational Burden (TMB)

Microsatellite Instability (MSI)

Neoantigen Prediction

Human Leukocyte Antigen (HLA) Typing

HLA Loss of Heterozygosity (LOH)

Oncogenic Virus

Mismatch Repair (MMR) Proteins by IHC1

PD-L1 Protein quantification by IHC1

Mechanisms of Tumor Resistance to Immunotherapy2

Immune Profile Score (IPS): ICI response prognosticator (available with concurrent xT and xR orders)

Tumor Mutational Burden (TMB)

Microsatellite Instability (MSI)

Neoantigen Prediction

Human Leukocyte Antigen (HLA) Typing

Oncogenic Virus

Mismatch Repair (MMR) Proteins by IHC1

PD-L1 Protein quantification by IHC1

Mechanisms of Tumor Resistance to Immunotherapy2

Gene Expression Target Profiling3

Neoantigen Prediction

Immune Infiltration

Oncogenic Virus

T-cell Receptor / B-cell Receptor Repertoire

Mismatch Repair (MMR) Proteins by IHC1

PD-L1 Protein quantification by IHC1

Immune Profile Score (IPS): ICI response prognosticator (available with concurrent xT and xR orders)

Blood Tumor Mutational Burden (bTMB) (xF+ only)

Microsatellite Instability (MSI) high status (xF/xF+)

Go beyond sequencing with powerful analytics

Tempus’ analytical capabilities leverage AI and machine learning to enhance sequencing data, enabling the identification of potential biomarkers that correlate with therapy response. Our proprietary tools uncover novel cancer dependencies and drug targets, particularly in IO-resistant populations. Tempus also offers supplementary data, custom analyses, and specialized algorithms as add-ons to meet your specific research objectives.4

Discover Tempus Lens for in-depth data and insights
image description

Understand ICI treatment response

Utilize Tempus’ Immune Profile Score (IPS), a first-of-its-kind multimodal algorithm that uses DNA and RNA to provide prognostic insights into potential outcomes following immune checkpoint inhibitor (ICI) treatment in metastatic solid tumors.

The algorithm generates a score that categorizes study participants into:

  • IPS-High: Indicates a higher likelihood of favorable outcomes with ICI treatment.
  • IPS-Low: Indicates a lower likelihood of favorable outcomes with ICI treatment.
Learn more about Immune Profile Score (IPS)
image description

Powering clinical development with data and technology

Tempus operates CAP-accredited, CLIA-certified robotic sequencing labs in Chicago, Atlanta, and Raleigh with automated bioinformatics and variant classification reporting. Sequencing is typically completed within a median of 8 days after receiving samples.

Download our lab overview
image description

Our Science

view all
  • UPCOMING WEBINAR:

    Clinical validation of a novel multi-omic algorithm for stratifying outcomes in a real-world cohort of metastatic solid cancer patients treated with immune checkpoint inhibitors

    The Immune Profile Score (IPS) is a validated multi-omic biomarker that provides prognostic insights into ICI treatment outcomes in advanced cancer patients. IPS-high patients consistently show longer overall survival (OS) across various subgroups, highlighting its potential to identify those who benefit from ICI beyond existing biomarkers.

    Read now
  • UPCOMING WEBINAR:

    Q&A: Advancing immunotherapy biomarker identification with Immune Profile Score (IPS)

    Jason Blue-Smith, VP & GM of Algos at Tempus, discusses the challenges in immunotherapy biomarker identification and how Tempus’ Immune Profile Score (IPS) offers solutions to these problems.

    Read now
  • UPCOMING WEBINAR:

    Detecting HLA loss of heterozygosity within a standard diagnostic sequencing workflow for prognostic and therapeutic opportunities

    This study presents the development and validation of an assay to detect HLA loss of heterozygosity (LOH) within the FDA-approved Tempus xT CDx diagnostic test. The assay demonstrated high predictive accuracy and revealed significant prognostic implications for non-small cell lung cancer patients, facilitating its use in precision oncology for diagnostic, prognostic, and therapeutic applications.

    Read now
  • UPCOMING WEBINAR:

    A multi-modal, pan-cancer atlas of tumor-immune states across primary and metastatic disease using a large, real-world database

    In a pan-cancer analysis, significant differences in tumor immune states were observed by primary and metastatic sites, and by indication, with important implications for IO-treatment strategies. These data provide valuable and timely insights for IO research, where simultaneous assessment of molecular, immune, and clinical traits is required.

    Read now
  • UPCOMING WEBINAR:

    Associations between multimodal immune biomarkers and clinical outcomes in a real-world non-small cell lung cancer cohort

    Here we demonstrate that RNA-based immune signatures are significantly associated with clinical benefit and may supplement well-established ICI biomarkers in therapy selection. These immune RNA-based signatures need to be prospectively validated in future studies.

    Read now
  1. Assessment of MMR proteins by IHC, including MLH1, MSH2, MSH6, and PMS2, as well as PD-L1 IHC, is available as an optional add-on for Tempus xT/xE orders. This service is not automatically included in every order and should be selected by the customer.
  2. Tempus provides information on multiple variants and features that have been reported to confer resistance to immunotherapy. This includes mutations and/or copy number alterations in immune-associated genes that affect antigen presentation or interferon signaling. (xT, xE only)
  3. Tempus performs RNA whole transcriptome sequencing when sufficient tissue samples are provided.
  4. The availability of supplementary data is dependent on the scope of the request.

Partner with us

With a broad range of laboratory services and data analysis that support immunotherapy development, Tempus has the solutions you need.